Our Next Show: New Type of Myeloma Treatment Called JSK Moving Forward with Dr. Paul Shami, MD, Huntsman Cancer, Thursday Jan 14 @ 3 pm CST
Dr. Paul Shami, MD is leader of the Acute Leukemia Program at Huntsman Cancer Institute of the University of Utah and Member and Clinical Investigator at HCI. Dr. Shami is on the Clinical Cancer Investigation Committee, the Academic Senate and Faculty Review Committee at the University of Utah in the Department of Internal Medicine.
Dr. Shami is also Founder and Chief Medical Officer of JSK Therapeutics Inc. He reviews publications including Leukemia, Blood, Clinical Cancer Research, Clinical and Laboratory Medicine, Leukemia and Lymphoma, Clinical and Laboratory Haematology, Oncogene, Expert Opinion on Drug Delivery, Cancer, Journal of Pharmacy and Pharmacology, Journal of the National Cancer Institute Editor, Leukemia Research and Treatment. Dr. Shami has received the Leukemia and Lymphoma Society Translational Research Award, the Rapid Access to Intervention Development (RAID) National Cancer Institute award, and the Chairmans citation for outstanding service in the fight against blood cancers from the LLS. Dr. Shami completed his education in Lebanon and his post-graduate work at Duke University.Thanks to our episode sponsor, Takeda Oncology.